• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Scientific Officer Betz Stephen F. exercised 18,000 shares at a strike of $1.91, increasing direct ownership by 18% to 117,713 units (SEC Form 4)

    12/29/25 4:36:41 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRNX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Betz Stephen F.

    (Last) (First) (Middle)
    C/O CRINETICS PHARMACEUTICALS, INC.
    6055 LUSK BOULEVARD

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Crinetics Pharmaceuticals, Inc. [ CRNX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Scientific Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    12/26/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/26/2025 M 18,000 A $1.91 117,713 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.91 12/26/2025 M 18,000 (1) 03/16/2028 Common Stock 18,000 $0 90,514 D
    Explanation of Responses:
    1. The option vested in 48 equal monthly installments beginning on April 16, 2018.
    Remarks:
    /s/ Tobin Schilke, as attorney-in-fact 12/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRNX

    DatePrice TargetRatingAnalyst
    7/10/2025$36.00Neutral
    Goldman
    3/25/2025$60.00Buy
    Stifel
    2/11/2025Buy
    TD Cowen
    2/4/2025Peer Perform
    Wolfe Research
    1/22/2025$55.00Hold → Buy
    Jefferies
    3/6/2024$68.00Buy
    Citigroup
    1/16/2024$50.00Overweight
    Morgan Stanley
    12/21/2023$35.00Hold
    Jefferies
    More analyst ratings

    $CRNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Kalofonos Isabel exercised 2,500 shares at a strike of $40.59 and sold $137,500 worth of shares (2,500 units at $55.00) (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    1/7/26 5:11:26 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Betz Stephen F. exercised 18,000 shares at a strike of $1.91, increasing direct ownership by 18% to 117,713 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    12/29/25 4:36:41 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Struthers Richard Scott exercised 44,742 shares at a strike of $13.09, increasing direct ownership by 14% to 364,759 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    12/18/25 6:54:46 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CRNX
    SEC Filings

    View All

    $CRNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics"), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45.95 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $350 million. In addition, Crinetics

    1/6/26 9:22:59 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics"), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $350.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock. All of the shares to be sold in the proposed offering are to be sold by Crinetics. There can be no assuran

    1/5/26 4:02:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

    Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Open-Label Extension of Phase 2 CAH Study With No Hepatic Transaminase Adverse Events Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cr

    1/5/26 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Crinetics Pharmaceuticals Inc.

    8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    1/7/26 4:39:24 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Crinetics Pharmaceuticals Inc.

    424B5 - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    1/7/26 4:03:53 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Crinetics Pharmaceuticals Inc.

    144 - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    1/5/26 4:43:08 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Crinetics Pharmaceuticals with a new price target

    Goldman initiated coverage of Crinetics Pharmaceuticals with a rating of Neutral and set a new price target of $36.00

    7/10/25 8:53:33 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Crinetics Pharmaceuticals with a new price target

    Stifel initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    3/25/25 8:26:55 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Crinetics Pharmaceuticals

    TD Cowen initiated coverage of Crinetics Pharmaceuticals with a rating of Buy

    2/11/25 7:03:38 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Leadership Updates

    Live Leadership Updates

    View All

    Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

    SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti

    2/24/25 8:30:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

    SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company's deep, innovative pipeline of candidates. "Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy," said Scott Struthers, Ph.D

    12/16/24 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

    SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. "Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the pharmaceutical industry is an invaluable addition to our talented scientific leadership team," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we forg

    5/30/24 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Financials

    Live finance-specific insights

    View All

    Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

    Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Open-Label Extension of Phase 2 CAH Study With No Hepatic Transaminase Adverse Events Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cr

    1/5/26 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

    SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. Conference Call and Webcast DetailsManagement will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible

    1/4/26 4:00:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

          PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends       Reiterates Cash Burn of $340-370M and Cash Runway into 2029       Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the third quarter ended September 30, 2025. "September 25, 2025 was a historic day for Crinetics with the approva

    11/6/25 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 7:55:29 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 5:46:54 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Crinetics Pharmaceuticals Inc.

    SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 1:22:38 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care